To PLEX or not to PLEX in natalizumab-associated PML

Neurology. 2017 Mar 21;88(12):1108-1109. doi: 10.1212/WNL.0000000000003747. Epub 2017 Feb 22.

Authors

Kenneth L Tyler¹, Timothy L Vollmer²

Affiliations

¹ From the Departments of Neurology (K.L.T., T.L.V.) and Medicine (Infectious Diseases) (K.L.T.), Immunology-Microbiology, University of Colorado School of Medicine, Aurora. ken.tyler@ucdenver.edu.
² From the Departments of Neurology (K.L.T., T.L.V.) and Medicine (Infectious Diseases) (K.L.T.), Immunology-Microbiology, University of Colorado School of Medicine, Aurora.

PMID: 28228561
DOI: 10.1212/WNL.0000000000003747

No abstract available

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Humans
Leukoencephalopathy, Progressive Multifocal / chemically induced*
Leukoencephalopathy, Progressive Multifocal / therapy*
Multiple Sclerosis / drug therapy
Natalizumab / adverse effects*
Plasma Exchange / methods*

Substances

Antibodies, Monoclonal, Humanized
Natalizumab